Praxis International Praxis is pleased to announce upcoming webinars on Becoming a Blueprint Community! The Blueprint for Safety
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Deep Learning Predicts the Malignant-Transformation-Free Survival of Oral Potentially Malignant Disorders Cancers | Free Full-Text | Deep Learning Predicts the Malignant-Transformation-Free Survival of Oral Potentially Malignant Disorders](https://pub.mdpi-res.com/cancers/cancers-13-06054/article_deploy/html/images/cancers-13-06054-g001-550.jpg?1638348733)
Cancers | Free Full-Text | Deep Learning Predicts the Malignant-Transformation-Free Survival of Oral Potentially Malignant Disorders
![Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors | Journal of Medicinal Chemistry Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.5b00810/asset/images/large/jm-2015-00810b_0014.jpeg)